Arcturus Therapeutics (ARCT) Short Interest Ratio & Short Volume $22.04 +2.65 (+13.64%) As of 02:02 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrendsBuy This Stock Arcturus Therapeutics Short Interest DataArcturus Therapeutics (ARCT) has a short interest of 5.95 million shares, representing 23.93% of the float (the number of shares available for trading by the public). This marks a 9.98% increase in short interest from the previous month. The short interest ratio (days to cover) is 10.3, indicating that it would take 10.3 days of the average trading volume of 519,281 shares to cover all short positions.Current Short Interest5,950,000 sharesPrevious Short Interest5,410,000 sharesChange Vs. Previous Month+9.98%Dollar Volume Sold Short$107.87 millionShort Interest Ratio10.3 Days to CoverLast Record DateSeptember 15, 2025Outstanding Shares27,160,000 sharesFloat Size24,860,000 sharesShort Percent of Float23.93%Today's Trading Volume626,835 sharesAverage Trading Volume519,281 sharesToday's Volume Vs. Average121% Short Selling Arcturus Therapeutics? Sign up to receive the latest short interest report for Arcturus Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Get Report View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartARCT Short Interest Over TimeARCT Days to Cover Over TimeARCT Percentage of Float Shorted Over Time Arcturus Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 9/15/20255,950,000 shares $107.87 million +10.0%23.9%10.3 $18.13 8/31/20255,410,000 shares $92.02 million +5.3%21.8%10.1 $17.01 8/15/20255,140,000 shares $100.13 million +17.6%20.7%9.4 $19.48 7/31/20254,370,000 shares $53.36 million -2.5%17.6%9.5 $12.21 7/15/20254,480,000 shares $58.91 million -11.1%18.0%10.1 $13.15 6/30/20255,040,000 shares $65.57 million +1.4%20.3%10.9 $13.01 6/15/20254,970,000 shares $61.53 million -9.6%20.0%11.2 $12.38 5/31/20255,500,000 shares $69.47 million +1.7%22.2%12.3 $12.63 5/15/20255,410,000 shares $62.97 million +5.3%21.8%12.7 $11.64 4/30/20255,140,000 shares $65.84 million +1.4%21.1%12.1 $12.81 Get the Latest News and Ratings for ARCT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Arcturus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 4/15/20255,070,000 shares $53.59 million +9.0%20.8%11.7 $10.57 3/31/20254,650,000 shares $49.24 million +5.4%19.1%10.7 $10.59 3/15/20254,410,000 shares $62.09 million +5.3%18.1%10.6 $14.08 2/28/20254,190,000 shares $70.35 million -1.0%17.2%10.1 $16.79 2/15/20254,230,000 shares $76.35 million -6.8%17.4%10.4 $18.05 1/31/20254,540,000 shares $77.04 million -9.9%18.5%10.6 $16.97 1/15/20255,040,000 shares $84.47 million +4.6%20.5%12.5 $16.76 12/31/20244,820,000 shares $81.80 million +8.6%19.6%12 $16.97 12/15/20244,440,000 shares $76.41 million +1.6%18.1%11.3 $17.21 11/30/20244,370,000 shares $80.15 million -2.5%17.8%11.1 $18.34 11/15/20244,480,000 shares $71.77 million -2.2%18.2%11.4 $16.02 10/31/20244,580,000 shares $81.20 million +3.4%18.5%12.8 $17.73 10/15/20244,430,000 shares $92.90 million -3.7%17.9%12 $20.97 9/30/20244,600,000 shares $106.77 million -12.1%18.6%11.8 $23.21 9/15/20245,230,000 shares $108.52 million -2.8%21.2%11.6 $20.75 8/31/20245,380,000 shares $113.52 million -1.5%21.8%10.5 $21.10 8/15/20245,460,000 shares $110.62 million +1.9%22.1%9.5 $20.26 7/31/20245,360,000 shares $125.75 million +2.9%21.7%9.1 $23.46 7/15/20245,210,000 shares $121.81 million +11.3%21.2%8.7 $23.38 6/30/20244,680,000 shares $113.96 million +6.9%19.0%7.6 $24.35 6/15/20244,380,000 shares $135.78 million +6.6%17.8%7.4 $31.00 5/31/20244,110,000 shares $159.51 million -0.5%16.7%7.4 $38.81 5/15/20244,130,000 shares $119.83 million -16.1%16.8%8.2 $29.02 4/30/20244,920,000 shares $125.80 million +6.7%20.0%9.7 $25.57 4/15/20244,610,000 shares $135.12 million -4.2%18.8%9.7 $29.31 3/31/20244,810,000 shares $162.43 million +14.3%19.6%10.6 $33.77 3/15/20244,210,000 shares $152.87 million -0.2%17.2%10 $36.31 2/29/20244,220,000 shares $163.57 million -6.6%17.3%10.1 $38.76 2/15/20244,520,000 shares $172.62 million +3.4%18.6%11.4 $38.19 1/31/20244,370,000 shares $144.08 million +5.3%18.0%10.3 $32.97 1/15/20244,150,000 shares $137.57 million +0.5%17.1%9.8 $33.15 12/31/20234,130,000 shares $130.22 million -6.8%17.0%10.1 $31.53 12/15/20234,430,000 shares $127.94 million -18.4%18.2%10.9 $28.88 11/30/20235,430,000 shares $129.99 million +7.1%22.3%13.5 $23.94 11/15/20235,070,000 shares $114.18 million +1.6%20.8%13.1 $22.52 10/31/20234,990,000 shares $95.31 million +4.2%20.6%13.6 $19.10 10/15/20234,790,000 shares $109.79 million +3.9%19.8%12.3 $22.92 9/30/20234,610,000 shares $117.79 million +10.0%19.0%10.8 $25.55 9/15/20234,190,000 shares $119.58 million +6.6%17.3%9.4 $28.54 8/31/20233,930,000 shares $119.28 million +0.3%16.2%8.8 $30.35 8/15/20233,920,000 shares $117.36 million +2.1%16.2%8.9 $29.94 7/31/20233,840,000 shares $134.25 million +5.8%15.9%8.6 $34.96 7/15/20233,630,000 shares $128.65 million +9.0%15.0%8.4 $35.44 6/30/20233,330,000 shares $95.50 million -8.0%13.8%7.7 $28.68 6/15/20233,620,000 shares $99.48 million +0.3%15.0%6.8 $27.48 5/31/20233,610,000 shares $98.70 million +8.7%15.0%7 $27.34 5/15/20233,320,000 shares $101.69 million +5.7%13.8%6.4 $30.63 4/30/20233,140,000 shares $83.59 million +11.7%13.7%6.4 $26.62 4/15/20232,810,000 shares $77.47 million +6.0%12.3%5.9 $27.57 3/31/20232,650,000 shares $63.52 million +4.3%11.6%5.8 $23.97 3/15/20232,540,000 shares $40.49 million +8.6%11.1%7.5 $15.94 2/28/20232,340,000 shares $38.03 million +4.9%10.2%5.8 $16.25 2/15/20232,230,000 shares $41.32 million +21.9%9.8%5.5 $18.53 1/31/20231,830,000 shares $38.67 million +9.6%8.0%3.8 $21.13 1/15/20231,670,000 shares $33.20 million -12.1%7.3%2.9 $19.88 12/30/20221,900,000 shares $32.22 million -27.8%8.3%3.3 $16.96 12/15/20222,630,000 shares $47.97 million -7.4%11.5%4.5 $18.24 11/30/20222,840,000 shares $52.37 million +9.2%12.4%5.2 $18.44 11/15/20222,600,000 shares $46.80 million -10.0%11.4%4.8 $18.00 10/31/20222,890,000 shares $51.15 million +9.5%12.6%5.6 $17.70 10/15/20222,640,000 shares $37.75 million +6.0%11.5%6.2 $14.30 9/30/20222,490,000 shares $36.90 million +9.7%10.9%5.7 $14.82 9/15/20222,270,000 shares $37.18 million +1.3%9.9%4.9 $16.38 8/31/20222,240,000 shares $31.45 million -14.2%9.8%4.1 $14.04 8/15/20222,610,000 shares $56.56 million -7.8%11.4%4.4 $21.67 7/31/20222,830,000 shares $49.67 million -2.1%12.4%4.5 $17.55 7/15/20222,890,000 shares $48.41 million -2.7%12.7%4.4 $16.75 6/30/20222,970,000 shares $46.75 million -12.1%13.1%4 $15.74 6/15/20223,380,000 shares $44.99 million +1.2%14.9%4.6 $13.31 5/31/20223,340,000 shares $66.40 million +8.1%14.7%5 $19.88 5/15/20223,090,000 shares $52.47 million +1.3%13.6%4.8 $16.98 4/30/20223,050,000 shares $59.11 million +24.0%13.4%5.1 $19.38 4/15/20222,460,000 shares $65.21 million -5.0%10.8%4 $26.51 3/31/20222,590,000 shares $69.83 million +9.8%11.4%5 $26.96 3/15/20222,360,000 shares $43.80 million -4.5%10.4%4.4 $18.56 2/28/20222,470,000 shares $59.21 million -4.6%10.9%4.3 $23.97 2/15/20222,590,000 shares $64.36 million -1.9%11.4%4.4 $24.85 1/31/20222,640,000 shares $68.98 million +17.3%11.6%4.2 $26.13 1/15/20222,250,000 shares $75.33 million -4.3%9.9%3.7 $33.48 12/31/20212,350,000 shares $86.97 million +10.9%10.4%4.1 $37.01 12/15/20212,120,000 shares $75.30 million -15.2%9.3%3.6 $35.52 11/30/20212,500,000 shares $99.38 million +12.1%11.0%5 $39.75 11/15/20212,230,000 shares $79.23 million +9.9%9.8%4.6 $35.53 10/29/20212,030,000 shares $91.25 million +8.0%9.3%3.3 $44.95 10/15/20211,880,000 shares $85.65 million -2.6%8.7%2.2 $45.56 9/30/20211,930,000 shares $92.22 million -8.1%8.9%2.3 $47.78 9/15/20212,100,000 shares $109.81 million -14.6%9.7%2.4 $52.29 8/31/20212,460,000 shares $134.83 million +8.9%11.4%2.8 $54.81 8/13/20212,260,000 shares $108.53 million -38.6%10.5%2.6 $48.02 7/30/20213,680,000 shares $115.22 million -1.6%18.1%4.4 $31.31 7/15/20213,740,000 shares $104.79 million -6.5%17.3%7.2 $28.02 6/30/20214,000,000 shares $135.36 million -8.3%18.5%7.5 $33.84 6/15/20214,360,000 shares $146.15 million -13.0%20.2%8.1 $33.52 5/28/20215,010,000 shares $146.39 million -2.9%23.2%9.1 $29.22 5/14/20215,160,000 shares $133.08 million +13.4%N/A7.8 $25.79 4/30/20214,550,000 shares $169.58 million +12.1%N/A6.2 $37.27 4/15/20214,060,000 shares $162.08 million +7.7%N/A4.9 $39.92 3/31/20213,770,000 shares $146.09 million +18.9%N/A3.2 $38.75 3/15/20213,170,000 shares $156.85 million -0.6%N/A1.8 $49.48 2/26/20213,190,000 shares $164.06 million +23.2%N/A1.7 $51.43 2/12/20212,590,000 shares $204.01 million -10.1%N/A1.4 $78.77 1/29/20212,880,000 shares $188.58 million -15.8%N/A1.5 $65.48 1/15/20213,420,000 shares $212.96 million +7.9%N/A1.8 $62.27 12/31/20203,170,000 shares $148.07 million -14.3%N/A1.9 $46.71 12/15/20203,700,000 shares $397.90 million -19.4%N/A3.7 $107.54 11/30/20204,590,000 shares $348.84 million -2.1%N/A5.1 $76.00 11/15/20204,690,000 shares $222.63 million +4.0%N/A6.5 $47.47 10/30/20204,510,000 shares $247.96 million +8.7%N/A6.6 $54.98 10/15/20204,150,000 shares $214.02 million +9.5%N/A6 $51.57 ARCT Short Interest - Frequently Asked Questions What is Arcturus Therapeutics' current short interest? Short interest is the volume of Arcturus Therapeutics shares that have been sold short but have not yet been covered or closed out. As of September 15th, traders have sold 5,950,000 shares of ARCT short. 23.93% of Arcturus Therapeutics' shares are currently sold short. Learn More on Arcturus Therapeutics' current short interest. What is a good short interest ratio for Arcturus Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ARCT shares currently have a short interest ratio of 10.0. Learn More on Arcturus Therapeutics's short interest ratio. Which institutional investors are shorting Arcturus Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Arcturus Therapeutics: Group One Trading LLC, Jane Street Group LLC, Caption Management LLC, Walleye Capital LLC, Walleye Trading LLC, and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Arcturus Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 23.93% of Arcturus Therapeutics' floating shares are currently sold short. Is Arcturus Therapeutics' short interest increasing or decreasing? Arcturus Therapeutics saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 5,950,000 shares, an increase of 10.0% from the previous total of 5,410,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Arcturus Therapeutics' float size? Arcturus Therapeutics currently has issued a total of 27,160,000 shares. Some of Arcturus Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Arcturus Therapeutics currently has a public float of 24,860,000 shares. How does Arcturus Therapeutics' short interest compare to its competitors? 23.93% of Arcturus Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Arcturus Therapeutics: IDEAYA Biosciences, Inc. (11.73%), Belite Bio, Inc. Sponsored ADR (0.62%), ImmunityBio, Inc. (8.59%), Arcutis Biotherapeutics, Inc. (13.39%), Recursion Pharmaceuticals, Inc. (39.65%), Mesoblast Limited (2.01%), Disc Medicine, Inc. (9.76%), Agios Pharmaceuticals, Inc. (8.63%), Denali Therapeutics Inc. (10.00%), Sarepta Therapeutics, Inc. (20.76%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Corporation ($8.81 billion), Canadian Natural Resources Limited ($5.82 billion), Reddit Inc. ($5.19 billion), Coinbase Global, Inc. ($4.52 billion), Robinhood Markets, Inc. ($4.30 billion), Charter Communications, Inc. ($3.75 billion), CoreWeave Inc. ($3.66 billion), Seagate Technology Holdings PLC ($3.57 billion), Live Nation Entertainment, Inc. ($3.33 billion), and Rocket Lab Corporation ($3.26 billion). View all of the most shorted stocks. What does it mean to sell short Arcturus Therapeutics stock? Short selling ARCT is an investing strategy that aims to generate trading profit from Arcturus Therapeutics as its price is falling. ARCT shares are trading up $2.83 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Arcturus Therapeutics? A short squeeze for Arcturus Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ARCT, which in turn drives the price of the stock up even further. How often is Arcturus Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ARCT, twice per month. The most recent reporting period available is September, 15 2025. More Short Interest Resources from MarketBeat Related Companies IDEAYA Biosciences Short Interest Belite Bio Short Interest ImmunityBio Short Interest Arcutis Biotherapeutics Short Interest Recursion Pharmaceuticals Short Interest Mesoblast Short Interest Disc Medicine Short Interest Agios Pharmaceuticals Short Interest Denali Therapeutics Short Interest Sarepta Therapeutics Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ARCT) was last updated on 10/14/2025 by MarketBeat.com Staff From Our PartnersNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredWhat Wall Street Won’t Say Out LoudDiscover the 7 key indicators before everyone else doesAmerican Alternative | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcturus Therapeutics Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcturus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
